Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 ...

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 programNurix DEL-AI drug ...

Nurix Therapeutics has widened its collaboration with Sanofi, granting the French pharmaceutical company an exclusive license to an undisclosed program targeting a previously undruggable transcription ...

French drugmaker Sanofi (Euronext: SAN) has appointed Chris Corsico as its new global head of development, according to an ...

Stock analysts at Leerink Partnrs raised their Q1 2025 earnings per share (EPS) estimates for Sanofi in a report released on ...

US Services’ rilzabrutinib orphan designation as a treatment of immunoglobulin G4-related disease, according to a ...

Banks including Goldman Sachs Group Inc. and Citigroup Inc. have wrapped up a €7.45 billion ($8.1 billion) sale of leveraged ...

Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...

"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...